Je veux savoir à propos de…

Federal Register / Vol. 86, No. 24 / Monday, February 8, 2021 / Notices OMB control number: 09380618;
Frequency: Quarterly and occasionally;
Affected Public: State, Local, or Tribal Governments; Number of Respondents:
50; Total Annual Responses: 40; Total Annual Hours: 3,200. For policy questions regarding this collection contact Stuart Goldstein at 410786
0694.
Dated: February 3, 2021.
William N. Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.
FR Doc. 202102524 Filed 2521; 8:45 am BILLING CODE 412001P

Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892
Virtual Meeting.
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892 301 8275819 gm145a@nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS
Dated: February 2, 2021.
Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
FR Doc. 202102495 Filed 2521; 8:45 am
National Institute on Drug Abuse;
Notice of Closed Meetings
BILLING CODE 414001P

jbell on DSKJLSW7X2PROD with NOTICES

Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; DeviceBased Treatments for Substance Use Disorders UG3/UH3, Clinical Trial Optional.
Date: February 26, 2021.
Time: 12:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892
Virtual Meeting.
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, 301 8275833, ivan.navarro@nih.gov.
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel;
Advancing HIV/AIDS Research through Computational Neuroscience FOA R01
Clinical Trial Optional.
Date: March 3, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.

VerDate Sep<11>2014

20:48 Feb 05, 2021

Jkt 253001

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Integrative and Clinical Endocrinology and Reproduction Study Section, February 18, 2021, 09:00 a.m. to February 19, 2021, 07:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the Federal Register on January 22, 2021, 86 FR 6659.
This notice is being amended to change the meeting date from 2/18/
20212/19/2021 to 2/18/2021. The meeting is closed to the public.
Dated: February 2, 2021.
Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.

8651

The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group; Neurological Sciences and Disorders C Translational Neural, Brain, and Pain Relief Devices.
Date: March 12, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate cooperative agreement applications.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 Virtual Meeting.
Contact Person: Diana M. Cummings, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Neurological Disorders and Stroke, NIH, NSC, 6001 Executive Blvd., Suite 3208, Rockville, MD 20852, cummingsdi@
ninds.nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS
Dated: February 2, 2021.
Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202102496 Filed 2521; 8:45 am BILLING CODE 414001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Center for Scientific Review; Notice of Closed Meetings
FR Doc. 202102492 Filed 2521; 8:45 am BILLING CODE 414001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

PO 00000

Frm 00074

Fmt 4703

Sfmt 4703

Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which
E:FRFM08FEN1.SGM

08FEN1